Avalo TherapeuticsAVTX
13F holders, Q3 2024 (September 30)29holders +8
10new positions
2sold out
$9.49avg. 13F price*
At the end of Q3 2024, 29 institutions reported holding Avalo Therapeutics Inc. (AVTX) in their 13F filings, up 8 from Q2 2024. 10 opened new positions and 2 sold out. The largest holders were Ikarian Capital, LLC ($9.2M), Deep Track Capital, LP ($9.2M) and Orbimed Advisors LLC ($9.2M).
- Company
- Avalo Therapeutics Inc.
- CUSIP
- 05338F306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $43.0M |
| Exits | 2 | $11K |
All 13F filers, Q2 2024 → Q3 2024: 5,886,765 shares bought and 929 shares sold, net +5,885,836 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 29 holders
| Ikarian Capital, LLC | 2.86% | Add +1673.0% | 970,359 | $9.2M |
| Deep Track Capital, LP | 0.29% | New | 967,000 | $9.2M |
| Orbimed Advisors LLC | 0.17% | New | 967,000 | $9.2M |
| Ra Capital Management, L.P. | 0.11% | New | 967,000 | $9.2M |
| BVF Inc. | 0.27% | New | 967,000 | $9.1M |
| Logos Global Management LP | 0.57% | No change | 539,079 | $5.1M |
| TCG Crossover Management, LLC | 0.39% | New | 483,000 | $4.6M |
| Commodore Capital LP | 0.29% | Add +1107.5% | 483,000 | $4.6M |
| Boothbay Fund Management, LLC | 0.05% | New | 164,092 | $1.6M |
| Sio Capital Management, LLC | 0.30% | No change | 71,458 | $679K |
| Affinity Asset Advisors, LLC | 0.07% | No change | 45,000 | $426K |
| Vanguard Group Inc. | 0.00% | No change | 10,368 | $98K |
| Geode Capital Management, LLC | 0.00% | New | 10,111 | $96K |
| UBS Group AG | 0.00% | Add +71.2% | 6,134 | $58K |
| Bank of America Corp. | 0.00% | No change | 5,601 | $53K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 376 | $4K |
| BlackRock, Inc. | 0.00% | — | 329 | $3K |
| Morgan Stanley | 0.00% | No change | 10 | $96 |
| BNP Paribas Financial Markets | 0.00% | No change | 4 | $38 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $19 |
| Group One Trading LLC | 0.00% | No change | 2 | $19 |
| Osaic Holdings, Inc. | 0.00% | No change | 2 | $19 |
| Wells Fargo & Company | 0.00% | No change | 1 | $10 |
| Jaffetilchin Investment Partners, LLC | 0.00% | New | 1 | $10 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $10 |
| Key Financial Inc | 0.00% | No change | 1 | $10 |
| Activest Wealth Management | 0.00% | No change | 1 | $10 |
| FMR LLC | 0.00% | Reduce -50.0% | 1 | $9 |
| Avion Wealth | 0.00% | New | 5 | $0 |
"% of holder's portfolio" is AVTX's weight in each manager's 13F, not the share of Avalo Therapeutics Inc. the manager owns.